Search results for "follicle"

showing 10 items of 137 documents

Effects of a ketogenic diet in overweight women with polycystic ovary syndrome.

2019

Abstract Background Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women during reproductive age. It is characterised clinically by oligo-ovulation or anovulation, hyper-androgenism, and the presence of polycystic ovaries. It is associated with an increased prevalence of metabolic syndrome, cardiovascular disease and type 2 diabetes. The onset of PCOS has been associated to several hereditary and environmental factors, but insulin resistance plays a key pathogenetic role. We sought to investigate the effects of a ketogenic diet (KD) on women of childbearing age with a diagnosis of PCOS. Methods Fourteen overweight women with diagnosis of PCOS underwent to a ketoge…

0301 basic medicinemedicine.medical_specialtyLow carbohydrate dietlcsh:Medicine030209 endocrinology & metabolismType 2 diabetesGeneral Biochemistry Genetics and Molecular BiologyBody Mass IndexAnovulation03 medical and health sciencesFollicle-stimulating hormoneHyperinsulinemia0302 clinical medicineSex hormone-binding globulinInsulin resistanceInternal medicinemedicinePCOSHumansInsulin030109 nutrition & dieteticsbiologybusiness.industryHyperinsulinemia Ketogenic diet Ketone bodies LCKD Low carbohydrate diet Overweight PCOSResearchlcsh:Rnutritional and metabolic diseasesGeneral MedicineLuteinizing HormoneOverweightKetogenic dietmedicine.diseaseLCKDPolycystic ovaryEndocrinologyDiabetes Mellitus Type 2Hyperinsulinemia; Ketogenic diet; Ketone bodies; LCKD; Low carbohydrate diet; Overweight; PCOSbiology.proteinLean body massKetone bodiesFemaleMetabolic syndromeInsulin ResistancebusinessDiet KetogenicSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' MotoriePolycystic Ovary SyndromeJournal of translational medicine
researchProduct

2020

In midlife, women experience hormonal changes due to menopausal transition. A decrease especially in estradiol has been hypothesized to cause loss of muscle mass. This study investigated the effect of menopausal transition on changes in lean and muscle mass, from the total body to the muscle fiber level, among 47–55-year-old women. Data were used from the Estrogenic Regulation of Muscle Apoptosis (ERMA) study, where 234 women were followed from perimenopause to early postmenopause. Hormone levels (estradiol and follicle stimulating hormone), total and regional body composition (dual-energy X-ray absorptiometry (DXA) and computed tomography (CT) scans), physical activity level (self-reported…

0303 health sciencesmedicine.medical_specialtyMuscle biopsymedicine.diagnostic_testbusiness.industrySkeletal muscle030209 endocrinology & metabolismGeneral Medicinemedicine.diseasePhysical activity levelMenopause03 medical and health sciencesFollicle-stimulating hormone0302 clinical medicineEndocrinologymedicine.anatomical_structureSarcopeniaInternal medicinemedicineLean body massbusiness030304 developmental biologyHormoneJournal of Clinical Medicine
researchProduct

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of th…

2016

Functional hypothalamic amenorrhea is a disorder characterized by cessation of menstrual cycles in the absence of organic disease. In most patients, it occurs in adult life after a stressful event and may be related to a condition of mild chronic energy deprivation. The endocrine pattern is characterized by low estrogen levels with an absent response to a progestogen challenge test and low-normal gonadotropin levels. A few studies have shown that some of these women may have some features of polycystic ovary syndrome; these features include an increased androgen response to gonadotropins, increased anti-Mullerian hormone levels, and altered ovarian morphology or increased ovarian size. Thes…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseases030209 endocrinology & metabolismOvaryOrganic diseaseHypothalamic disease03 medical and health sciencesFollicle-stimulating hormoneYoung Adult0302 clinical medicineInternal medicinemedicineHumansTestosteroneAmenorrheaRetrospective Studies030219 obstetrics & reproductive medicinebiologybusiness.industryOvaryAndrostenedioneObstetrics and GynecologyAnti-Müllerian hormoneDehydroepiandrosteroneOrgan SizeLuteinizing Hormonemedicine.diseasePolycystic ovaryEndocrinologymedicine.anatomical_structureCase-Control Studiesbiology.proteinAmenorrheaFemalemedicine.symptomFollicle Stimulating HormoneLuteinizing hormonebusinessHypothalamic DiseasesPolycystic Ovary SyndromeAmerican journal of obstetrics and gynecology
researchProduct

Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual func…

2017

Since features of polycystic ovary syndrome (PCOS) have been found to be prevalent in women with functional hypothalamic amenorrhea (FHA), we wished to determine what happens to these features after recovery of menstrual function in FHA Design: Prospective cohort study. Twenty-eight women with FHA and 30 age-matched ovulatory controls were studied.Twenty-eight women with FHA and 30 age-matched ovulatory controls were studied. We measured serum estradiol, LH, FSH, testosterone, DHEAS, anti-Mullerian hormone (AMH), body mass index, and ovarian morphology on transvaginal ultrasound.At baseline, 12 of the 28 women (43%) had increased AMH (4.7 ng/mL), and higher testosterone and larger ovaries c…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismHypothalamic amenorrheaYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicinemedicineHumansTestosteroneProspective StudiesAmenorrheaUltrasonography030219 obstetrics & reproductive medicineEstradiolDehydroepiandrosterone Sulfatebusiness.industryPolycystic ovary syndrome (PCOS)OvaryObstetrics and GynecologyTestosterone (patch)Luteinizing Hormonemedicine.diseasePolycystic ovaryhumanitiesMenstruationEndocrinologyOvarian morphologyFemaleFollicle Stimulating HormonebusinessHypothalamic DiseasesPolycystic Ovary SyndromeGynecological Endocrinology
researchProduct

AMH MEASUREMENT VERSUS OVARIAN ULTRASOUND IN THE DIAGNOSIS OF POLYCYSTIC OVARY SYNDROME IN DIFFERENT PHENOTYPES.

2015

This study was designed to assess the value of serum anti-Müllerian hormone (AMH) in the diagnosis of polycystic ovary syndrome (PCOS) in various phenotypes and to assess ovarian ultrasound parameters.We performed a retrospective matched controlled study of 113 females with various PCOS phenotypes and 47 matched controls. The diagnostic utility of AMH measurement and ovarian ultrasound were compared. Using receiver operating characteristic (ROC) curve analyses, the threshold for AMH (4.7 ng/mL) and ultrasound parameters (follicle number per ovary [FNPO]22 and ovarian volume [OV]8 cc) were established.In the entire cohort, AMH had a low sensitivity of 79%; while FNPO and OV were 93% and 68%,…

AdultAnti-Mullerian Hormoneendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismOvaryDiagnostic Techniques Endocrine03 medical and health sciencesFollicleYoung Adult0302 clinical medicineEndocrinologymedicineHumansRetrospective StudiesUltrasonographyGynecology030219 obstetrics & reproductive medicineReceiver operating characteristicbiologybusiness.industryUltrasoundOvaryCase-control studyAnti-Müllerian hormoneRetrospective cohort studyGeneral MedicinePolycystic ovaryfemale genital diseases and pregnancy complicationsmedicine.anatomical_structurePhenotypeROC CurveCase-Control Studiesbiology.proteinFemalebusinessPolycystic Ovary SyndromeEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
researchProduct

Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society

2014

BACKGROUND The diagnosis of polycystic ovary syndrome (PCOS) relies on clinical, biological and morphological criteria. With the advent of ultrasonography, follicle excess has become the main aspect of polycystic ovarian morphology (PCOM). Since 2003, most investigators have used a threshold of 12 follicles (measuring 2-9 mm in diameter) per whole ovary, but that now seems obsolete. An increase in ovarian volume (OV) and/or area may also be considered accurate markers of PCOM, yet their utility compared with follicle excess remains unclear. METHODS Published peer-reviewed medical literature about PCOM was searched using PubMed.gov online facilities and was submitted to critical assessment b…

AdultAnti-Mullerian Hormonemedicine.medical_specialtyAdolescentPopulationOvaryBiologyFollicleYoung AdultOvarian FollicleTerminology as TopicmedicineHumansOvarian follicleeducationGynecologyeducation.field_of_studySurrogate endpointOvaryObstetrics and GynecologyReproducibility of ResultsAnti-Müllerian hormoneAntral folliclePolycystic ovarymedicine.anatomical_structureReproductive Medicinebiology.proteinFemaleBiomarkersPolycystic Ovary Syndrome
researchProduct

The endocrine pattern of late onset adrenal hyperplasia (21-hydroxylase deficiency)

1984

We describe 5 adult women with severe hirsutism due to late onset 21-hydroxylase deficiency. Diagnosis was performed on the finding of high serum 17-hydroxyprogesterone (17OHP) levels with a marked hyperresponse to an ACTH test. The endocrine study showed in most patients a gonadotropin behavior similar to that observed in classical polycystic ovary (PCO) syndrome. Prolactin levels were slightly increased in basal conditions and presented an exaggerated response to TRH stimulation.

AdultHirsutismendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismLate onsetEndocrinologyAdrenocorticotropic HormoneInternal medicineHydroxyprogesteronesmedicineHumansEndocrine systemGonadal Steroid HormoneshirsutismAdrenal Hyperplasia Congenitalbiologybusiness.industry17-alpha-HydroxyprogesteroneVirilization21-HydroxylaseLuteinizing Hormonemedicine.diseasePolycystic ovaryProlactinProlactinEndocrinologySteroid Hydroxylasesbiology.proteinFemaleSteroid 21-HydroxylaseFollicle Stimulating Hormonemedicine.symptomGonadotropinbusinesshormones hormone substitutes and hormone antagonistsJournal of Endocrinological Investigation
researchProduct

Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis

2011

Objective: To analyze the impact of LH administration on cycle outcome in ovarian stimulation with GnRH antagonists. Design: Randomized, open-label, controlled trial performed in two age subgroups. Recombinant (r) FSH versus rFSH + rLH administration was compared. Setting: University-affiliated private infertility clinic. Patient(s): Up to 35 years old (n = 380) and aged 36 to 39 years (n = 340), undergoing their first or second IVF cycle. Intervention(s): Recombinant LH administration since stimulation day 1. Main Outcome Measure(s): Implantation rate, ongoing pregnancy rate. Result(s): In the young population, implantation rates were similar: 27.8% versus 28.6%, odds ratio (OR) 1.03 (95% …

AdultInfertilitymedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentGonadotropin-releasing hormone antagonistGonadotropin-Releasing HormoneOvulation InductionPregnancymedicineGnRH antagonistHumansEmbryo ImplantationSperm Injections IntracytoplasmicGynecologyPregnancyIn vitro fertilisationbusiness.industryObstetrics and GynecologyOdds ratioLuteinizing Hormonemedicine.diseaseRecombinant ProteinsConfidence intervalPregnancy rateReproductive Medicineluteinizing hormoneDrug Therapy CombinationFemaleOvarian stimulationFollicle Stimulating HormoneLuteinizing hormonebusinessInfertility Femalein vitro fertilizationMaternal Age
researchProduct

Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradi…

1999

A total of 30 young infertile patients who exhibited a poor response in two previous consecutive cycles, despite having normal basal follicle stimulating hormone (FSH) and oestradiol concentrations, were invited to participate in a prospective randomized study comparing the clinical efficacy of recombinant (rFSH) and urinary (uFSH) follicle stimulating hormone. An evaluation of the total dose used (3800 IU versus 4600 IU, P < 0.05) and duration of treatment (10.2 days versus 13.2 days, P < 0.05) showed a significantly shorter treatment period as well as a significantly lower total dose of FSH required to induce ovulation successfully in the group of patients treated with rFSH. Significantly…

AdultInfertilitymedicine.medical_specialtymedicine.drug_classUrinary systemmedia_common.quotation_subjectBiologyBasal (phylogenetics)Follicle-stimulating hormoneOvulation InductionPregnancyInternal medicinemedicineHumansEmbryo ImplantationProspective StudiesOvulationmedia_commonPregnancyEstradiolRehabilitationPregnancy OutcomeObstetrics and Gynecologymedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineEstrogenFemaleFollicle Stimulating HormoneGonadotropinHuman Reproduction
researchProduct